The expansion is said to increase the plant’s capacity by three times and would help restore supply levels for some of its important medicines, inpharm.com reported.
The facility exports medicines to over 70 countries around the world.
Waterford site will take care of the US supplies of Genzyme’s rare disease drugs including Cerezyme (imiglucerase), Myozyme (alglucosidase alfa) for Pompe disease, Fabrazyme (agalsidase beta) for Fabry disease and Thyrogen (thyrotropin alfa) for post-operative thyroid cancer patients.